BSE Live
Apr 08, 16:01Prev. Close
57.99
Open Price
60.00
Bid Price (Qty.)
58.98 (48)
Offer Price (Qty.)
60.00 (1496)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Bacil Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 | |
| Diluted EPS (Rs.) | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 | |
| Cash EPS (Rs.) | 0.29 | -0.09 | -0.15 | -5.91 | -0.36 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 18.20 | 1.86 | 1.68 | 1.88 | 2.13 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 18.20 | 1.86 | 1.68 | 1.88 | 2.13 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PBDIT/Share (Rs.) | 0.29 | -0.09 | -0.15 | -5.91 | -0.36 | |
| PBIT/Share (Rs.) | 0.29 | -0.09 | -0.16 | -5.91 | -0.37 | |
| PBT/Share (Rs.) | 0.29 | -0.09 | -0.16 | -5.91 | -0.37 | |
| Net Profit/Share (Rs.) | 0.29 | -0.09 | -0.16 | -5.91 | -0.37 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Return on Networth / Equity (%) | 1.58 | -4.85 | -9.26 | -315.24 | -17.19 | |
| Return on Capital Employed (%) | 1.60 | -4.86 | -9.26 | -315.26 | -17.22 | |
| Return on Assets (%) | 1.57 | -4.44 | -9.03 | -303.54 | -5.85 | |
| Total Debt/Equity (X) | 0.01 | 0.08 | 0.02 | 0.03 | 0.13 | |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 17.21 | 0.46 | 8.19 | 10.63 | 1.04 | |
| Quick Ratio (X) | 17.21 | 0.46 | 8.19 | 10.63 | 1.04 | |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 56.67 | 9.61 | 3.57 | 3.54 | 2.11 | |
| EV/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA (X) | 138.82 | -168.53 | -35.97 | -0.92 | -9.00 | |
| MarketCap/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 2.33 | 7.87 | 3.25 | 3.06 | 1.46 | |
| Price/Net Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | 0.01 | -0.01 | -0.03 | -1.03 | -0.12 |
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth